Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is now up 20.88% compared to a 12-month low of $2.25. We have seen the price to move -9.33% lower and get settled at $2.72 on 3/22/2019. At recent session, it appeared stuck in a range of $2.66 to $2.98. This company shares are 502.94% off its target price of $16.4 and the current market capitalization stands at $81.49M. The recent change has given its price a -3.09% deficit over SMA 50 and -84.11% deficit over its 52-week high. The stock witnessed -9.63% declines, -22.95% declines and -67.15% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IDRA’s volatility during a week at 11.67% and during a month it has been found around 8.95%.

Idera Pharmaceuticals, Inc. (IDRA) Top Holders

Institutional investors currently hold around $33 million or 46.5% in IDRA stock. Look at its top three institutional owners: Baker Bros. Advisors Lp owns $13.16 million in Idera Pharmaceuticals, Inc., which represents roughly 16.14% of the company’s market cap and approximately 39.86% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 1,478,231 shares of the stock are valued at $4.02 million. The third largest holder is Millennium Management Llc, which currently holds $1.64 million worth of this stock and that ownership represents nearly 2.01% of its market capitalization.

Idera Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 48 institutional holders increased their position in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) by some 1,666,768 shares, 25 decreased positions by 1,230,364 and 21 held positions by 9,392,663. That puts total institutional holdings at 12,289,795 shares, according to SEC filings. The stock grabbed 21 new institutional investments totaling 950,583 shares while 10 institutional investors sold out their entire positions totaling 172,325 shares.

Idera Pharmaceuticals, Inc. (IDRA) Analyst Guide

Several analysts have released their opinion on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.71 average brokerage recommendation [T1].